Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 2, 2000, Pages 462-466

  Jones, Mark E ^a   Sahm, Daniel F ^b   Martin, Nele ^c   Scheuring, Sibylle ^c   Heisig, Peter ^d   Thornsberry, Clyde ^b   Köhrer, Karl ^c   Schmitz, Franz Josef ^c  

^a MRL Pharmaceutical Services   (Netherlands)

^b MRL Pharmaceutical Services   (United States)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLINAFLOXACIN; GATIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SITAFLOXACIN; SPARFLOXACIN; TROVAFLOXACIN;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; CONTROLLED STUDY; GENE FREQUENCY; GENE MUTATION; GEOGRAPHIC DISTRIBUTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; STREPTOCOCCUS PNEUMONIAE;

ANTI-INFECTIVE AGENTS; BACTERIAL PROTEINS; DNA GYRASE; DNA TOPOISOMERASE IV; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; GENE FREQUENCY; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; RESPIRATORY SYSTEM; STREPTOCOCCUS PNEUMONIAE;

EID: 0033964495     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.2.462-466.2000     Document Type: Article

References (35)

1. Akasaka, T., S. Kurosaka, Y. Uchida, M. Tanaka, K. Sato, and I. Hayakawa. 1998. Antibacterial activities and inhibitory effects of sitafloxacin (DU-6859a) and its optical isomers against type II topoisomerases. Antimicrob. Agents Chemother. 42:1284-1287.
2. Ausubel, F., R. Brent, R. Kingston, D. Moore, J. Seidman, J. Smith, and K. Struhl. 1989. Current protocols in molecular biology. John Wiley & Sons, Inc., New York, N.Y.
3. Balas, D., E. Fernandez-Moreiera, and A. G. DeLaCampa. 1998. Molecular characterization of the gene encoding the DNA gyrase A subunit of Streptococcus pneumoniae. J. Bacteriol. 180:2854-2861.
4. Baquero, F. 1996. Epidemiology and management of penicillin resistant pneumococci. Curr. Opin. Infect. Dis. 9:372-279.
5. Brenwald, N. P., M. J. Gill, and R. Wise. 1998. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2032-2035.
6. Chen, D. K., A. McGeer, J. C. de Azavedo, and D. E. Low. 1999. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N. Engl. J. Med. 341:233-239.
7. Dalhoff, A., U. Peterson, and R. Enderman. 1996. In vitro activities of BAY12-8039, a new 8-methoxyquinolone. Chemotherapy 42:410-425.
8. Doern, G. V., A. Brueggeman, H. P. Holley, Jr., and A. M. Rauch. 1996. Antimicrobial resistance of Streptococcus pneumoniae recovered from out-patients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob. Agents Chemother. 40:1208-1213.
9. Doern, G. V., M. A. Pfaller, K. Kugler, J. Freeman, and R. N. Jones. 1998. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY Antimicrobial Surveillance Program. Clin. Infect. Dis. 27:764-770.
10. Ednie, L. M., M. R. Jacobs, and P. C. Appelbaum. 1998. Comparative activities of clinafloxacin against gram-positive and -negative bacteria. Antimicrob. Agents Chemother. 42:1269-1273.
11. Felmingham, D., M. J. Robbins, K. Ingley, I. Mathias, H. Bhogal, A. Leaky, G. L. Ridgeway, and R. N. Gruneburg. 1997. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. J. Antimicrob. Chemother. 39:S43-S49.
12. Fu, K. P., S. C. Lafredo, B. Foleno, D. M. Isaacson, J. R. Barret, A. J. Tobia, and M. E. Rosenthal. 1992. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob. Agents Chemother. 36:860-866.
13. Gill, M. J., N. P. Brenwald, and R. Wise. 1999. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:187-189.
14. Gootz, T. D., R. Zanieski, S. Haskell, B. Schmeider, J. Tankovic, D. Girard, P. Courvalin, and R. J. Polzer. 1996. Activity of the new fluoroquinolone trovafloxacin (CP-99, 219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2691-2697.
15. Hosaka, M., T. Yasue, H. Fukuda, H. Tomizawa, H. Aoyama, and K. Hirai. 1992. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob. Agents Chemother. 36:2108-2117.
16. Janoir, C., V. Zeller, M.-D. Kitzis, N. J. Moreau, and L. Gutmann. 1996. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob. Agents Chemother. 40:2760-2764.
17. Jorgensen, J. H., L. M. Weigel, M. J. Ferraro, J. M. Swenson, and F. C. Tenover. 1999. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci. Antimicrob. Agents Chemother. 43:329-334.
18. Muñoz, R., and A. G. De La Campa. 1996. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob. Agents Chemother. 40:2252-2257.
19. National Committee for Clinical Laboratory Standards. 1998. Performance standards for antimicrobial susceptibility testing: eighth informational supplement. NCCL document M100-S8. National Committee for Clinical Laboratory Standards, Villanova, Pa.
20. Pan, X.-S., and L. M. Fisher. 1996. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance. J. Bacteriol. 178:4060-4069.
21. Pan, X.-S., J. Ambler, S. Mehtar, and L. M. Fisher. 1996. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2321-2326.
22. Pan, X.-S., and L. M. Fisher. 1998. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2810-2816.
23. Perichon, B., J. Tankovic, and P. Courvalin. 1997. Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:1166-1167.
24. Sahm, D. F., M. E. Jones, M. L. Hickey, D. R. Diakun, S. Mani, and C. Thornsberry. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998. J. Antimicrob. Chemother, in press.
25. Schmitz, F.-J., M. E. Jones, B. Hofmann, B. Hansen, S. Scheuring, M. Luckefahr, A. Fluit, J. Verhoef, U. Hadding, H.-P. Heinz, and K. Köhrer. 1998. Characterization of grlA, grlB, gyrA, and gyrB in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC. Antimicrob. Agents Chemother. 42:1249-1252.
26. Schmitz, F.-J., M. Lückefahr, B. Engler, B. Hofmann, J. Verhoef, A. C. Fluit, H.-P. Heinz, and M. E. Jones. 1998. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activity of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother. 42:807-810.
27. Taba, H., and N. Kusano. 1998. Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genes. Antimicrob. Agents Chemother. 42:2193-2196.
28. Tankovic, J., B. Perichon, J. Duval, and P. Courvalin. 1996. Contribution of mutations in gyrA and parC genes to ftuoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob. Agents Chemother. 40:2505-2510.
29. Thornsberry, C., M. L. Hickey, J. Kahn, Y. Mauriz, and D. F. Sahm. 1999. Surveillance of antimicrobial resistance among respiratory tract pathogens in the United States, 1997-1998. Drugs 58(Suppl. 2):361-363.
30. Thornsberry, C., M. L. Hickey, M. E. Jones, I. A. Critchley, G. P. Park, and D. F. Sahm. 1999. International surveillance of susceptibility to levofloxacin and other agents among respiratory pathogens. Drugs 58(Suppl. 2):364-365.
31. Thornsberry, C., P. Ogilvie, J. Kahn, and Y. Mauriz. 1997. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. Diagn. Microbiol. Infect. Dis. 29:249-257.
32. Tomasz, A. 1994. Multiple antibiotic resistance pathogenic bacteria - a report on the Rockefeller University Workshop. N. Engl. J. Med. 330:1247-1251.
33. Varon, E., C. Janoir, M.-D. Kitzis, and L. Gutmann. 1999. ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:302-306.
34. Visser, M. R., I. M. Hoepelman, H. Beumer, and J. Verhoef. 1991. Comparative in vitro antibacterial activity of sparfloxacin (AT-4140; RPR64206), a new quinolone. Antimicrob. Agents Chemother. 35:858-868.
35. Wiedemann, B., and P. Heisig. 1997. Antibacterial activity of grepafloxacin. J. Antimicrob. Chemother. 40:S19-S25.